RT Journal Article
SR Electronic
T1 A Long-Acting Injectable Dosage Form for a Somatastatin Analog
JF PDA Journal of Pharmaceutical Science and Technology
JO PDA J Pharm Sci Technol
FD Parenteral Drug Association (PDA)
SP 234
OP 236
VO 38
IS 6
A1 Deyoung, Joyce L.
A1 Lien, Eric L.
YR 1984
UL http://journal.pda.org/content/38/6/234.abstract
AB In an attempt to prolong the activity of Wy-41,747, a somatostatin analog that has been shown to improve diabetic control in type I human diabetics, the peptide was adsorbed on zinc phosphate. A flocculated suspension was produced that extended the growth hormone suppressing effects of Wy-4l, 747 in rats to at least 17 hr, compared to 2 hr when the peptide is administered dissolved in saline. A suspension prepared using somatostatin in place of Wy-41,747 was not flocculated and gave no prolongation of activity, suggesting that no adsorption occurred. The presence of histidine residues in Wy-41,747 that are not present in somatostatin is postulated to be the reason for the success of the formulation.